RE:RE:RE:RE:RE:RE:RE:RE:I sense displeasure ...Case in point, Moderna is setting up an office with staff here in Canada to help with the distribution of the vaccine, they are not using re-vendors and pay fees. Many global biotech are doing the same and by passing re-vendors for their blockbuster drugs unless companies have participated/joint venture with the development of the drugs. GUD and other like it may become dodo birds if they do not change their business models. Time will tell and I hope to be proven wrong. Where are the drug licencing deals seven Years later and now with the larger Latam market? Anyone …has a list for the past 14 months? I would like to know? MNGT needs to adress investors either good or bad and not silence as the status quo